Progeria

Definition and Etiology

Hutchinson-Gilford Progeria Syndrome (HGPS) is an ultra-rare, fatal, autosomal dominant segmental progeroid syndrome characterized by premature, accelerated aging, severe premature atherosclerosis, and early death.

• Genetic Mutation: Caused by a de novo, heterozygous, silent point mutation in the LMNA gene on chromosome 1q22.
• Common Allele: G608G ($c.1824C>T$), which accounts for over 90% of cases.
• Pathogenesis: The mutation activates a cryptic splice site in exon 11, leading to the deletion of 50 amino acids near the C-terminus of the Prelamin A protein.
• Progerin Production: The truncated, permanently farnesylated mutant protein is called Progerin. Unlike normal Lamin A, progerin cannot be cleaved from the nuclear membrane, remaining intercalated in the nuclear envelope.
• Cellular Toxicity: Accumulated progerin causes nuclear blebbing, loss of heterochromatin, impaired DNA double-strand break repair, premature cellular senescence, and accelerated apoptosis, particularly affecting mesenchymal stem cell lineages.

Clinical Features

Infants typically appear normal at birth. Diagnostic features manifest sequentially during the first two years of life.

Cutaneous and Structural Manifestations

• Facies: "Sculptured" or bird-like facies with a pinched nose, micrognathia, prominent eyes (due to lagophthalmos), and retrognathia.
• Alopecia: Progressive loss of scalp hair, eyebrows, and eyelashes, typically beginning in the first year of life.
• Skin Changes: Sclerodermatous, taut skin on the abdomen and thighs; generalized lipodystrophy (loss of subcutaneous fat) leading to highly visible, prominent superficial veins.
• Dentition: Delayed eruption of primary and secondary teeth; crowding and double rows of teeth.

Musculoskeletal Features

• Growth Failure: Severe, symmetric growth restriction starting in infancy. Proportional short stature with low weight-for-height.
• Skeletal Deformities: Short, dystrophic clavicles, pyriform (pear-shaped) thorax, and coxa valga.
• Acro-osteolysis: Progressive resorption of the terminal phalanges of the fingers and toes.
• Joint Contractures: "Horse-rider" stance due to progressive tightening of the joint capsules, limiting extension of the knees, hips, and elbows.

Cardiovascular and Cerebrovascular Features

• Accelerated Atherosclerosis: Widespread, severe, non-atheromatous arteriosclerosis driven by smooth muscle cell loss in the tunica media of large arteries.
• Cardiovascular: Left ventricular hypertrophy, mid-systolic murmurs, progressive congestive heart failure, and myocardial infarction.
• Cerebrovascular: Recurrent ischemic strokes, silent infarcts, transient ischemic attacks (TIAs), leading to progressive neurological deficit.

Note: Cognitive development, memory, and motor skills remain entirely normal and age-appropriate.

Investigations

Genetic and Molecular Testing

• Sequence Analysis: Confirms the heterozygous $c.1824C>T$ mutation in the LMNA gene. This is the diagnostic gold standard.

Radiographic Evaluation

• Skeletal Survey: Shows osteolysis of distal phalanges, clavicular resorption, thinning of long bones, coxa valga, and delayed anterior fontanelle closure.
• Dual-Energy X-ray Absorptiometry (DEXA): Reveals low bone mineral density relative to age-matched controls, with altered structural geometry.

Cardiovascular and Cerebrovascular Monitoring

• Echocardiography: Evaluates diastolic and systolic function, left ventricular mass index (LVMI), and valvular calcification (aortic and mitral stenosis/regurgitation).
• Electrocardiogram (ECG): Monitors for left ventricular hypertrophy, ST-T wave changes, or arrhythmias signaling myocardial ischemia.
• Carotid Duplex Ultrasound & Pulse Wave Velocity (PWV): Measures arterial stiffness and internal carotid artery stenosis.
• Brain MRI / MRA: Detects silent cerebral infarctions, territorial strokes, and progressive steno-occlusive arterial disease.

Biochemical Parameters

• Basic metabolic panel is typically normal. Insulin resistance and mild hyperlipidemia may develop later in the course of the disease.

Differential Diagnosis

• Werner Syndrome (Adult Progeria): Onset in adolescence; caused by WRN gene mutations; characterized by cataracts and hypogonadism.
• Nestor-Guillermo Progeria Syndrome (NGPS): Caused by BANF1 mutations; features severe skeletal abnormalities but lacks early cardiovascular mortality.
• Mandibuloacral Dysplasia (MAD): Mutations in LMNA or ZMPSTE24; presents with mandibular hypoplasia, acro-osteolysis, and partial lipodystrophy.
• Cockayne Syndrome: Features microcephaly, severe neurodevelopmental delay, and cutaneous photosensitivity.

Management

There is no definitive cure for HGPS. Management relies on disease-modifying pharmacotherapy alongside aggressive supportive care.

Disease-Modifying Therapy

• Lonafarnib (Farnesyltransferase Inhibitor): Approved by the FDA/EMA for patients 12 months of age and older.
  • Mechanism: Inhibits the farnesylation of prelamin A and progerin, preventing its accumulation at the nuclear membrane.
  • Efficacy: Increases lifespan by an average of 2.5 to 4.3 years, reduces arterial stiffness, and lowers the risk of thromboembolic stroke.
• Combination Strategies (Clinical Trials): Lonafarnib plus mTOR inhibitors (Everolimus) to enhance the autophagic clearance of intracellular progerin.

Cardiovascular Support

• Antiplatelet Therapy: Low-dose Aspirin (2–3 mg/kg/day) to prevent thromboembolic stroke and myocardial infarction.
• Antihypertensive and Afterload Reduction: ACE inhibitors (e.g., Enalapril) or Beta-blockers to manage hypertension, reduce myocardial work, and address congestive heart failure.
• Statins: Considered for endothelial protection and lipid optimization, although standard atherosclerosis plaques are absent.

Supportive and Symptomatic Care

• Nutrition: High-calorie, nutrient-dense diet to combat hypermetabolism and lipodystrophy. Gastrostomy tube placement if nutritional goals cannot be met orally.
• Physical and Occupational Therapy: Active and passive stretching exercises to maintain joint mobility, preserve ambulation, and delay fixed contractures.
• Hydrotherapy: Improves joint range of motion with low mechanical stress.
• Dental Care: Regular professional extraction of retained primary teeth to prevent painful crowding.
• Podiatry: Customized shoe inserts to pad the feet, compensating for the lack of subcutaneous plantar fat padding.

Prognosis and Follow-up

• Mortality: The disease is uniformly fatal. The median lifespan without targeted therapy is approximately 14.5 years. With early, continuous Lonafarnib therapy, survival can extend past 18 years.
• Cause of Death: More than 90% of patients succumb to cardiovascular complications, primarily acute myocardial infarction or refractory congestive heart failure, or cerebrovascular accidents (hemiplegic stroke).
• Monitoring Frequency: Semiannual clinical examinations with formal cardiovascular and cerebrovascular assessments (Echocardiography, ECG, Carotid Doppler) performed every 6 to 12 months.